A recent study has revealed favorable outcomes regarding the efficacy of alpha-lipoic acid (ALA) supplementation in combating hepatic steatosis among individuals with non-alcoholic fatty liver disease (NAFLD).

This randomized clinical trial led by Mehrangiz Ebrahimi-Mameghani et al. focused on evaluating the impact of ALA supplementation on inflammatory and metabolic markers (Fetuin-A, Sirtuin1 [SIRT-1], Cytokeratin 18 [CK-18]) associated with NAFLD in 50 patients.

These patients were divided into two groups to receive either two ALA capsules (ALA 600 mg per capsule plus vitamin E 400 mg daily) or two placebo capsules (together with vitamin E 400 mg daily). Results showed that ALA supplementation was significantly more effective than placebo in reducing hepatic steatosis by at least 1 grade. Noteworthy reductions in homeostasis model assessment for insulin resistance (HOMA-IR) score, insulin levels, and Fetuin-A levels in ALA supplemented group were found.